why choose us

First received: January 26, 2023

Clinical Trial: A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Focal Onset Seizures

Study Type: INTERVENTIONAL


Official Title: A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures

Brief Summary: The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.

Read more